I. Klaman

发表

Transcriptional census of 36 microdissected colorectal cancers yields a gene signature to distinguish UICC II and III

Stefan Roepcke, C. Pilarsky, A. Rosenthal, 2006, International journal of cancer.

Genome-wide expression patterns of invasion front, inner tumor mass and surrounding normal epithelium of colorectal tumors

Stefan Roepcke, C. Pilarsky, A. Rosenthal, 2007, Molecular Cancer.

An expression module of WIPF1-coexpressed genes identifies patients with favorable prognosis in three tumor types

Christian Pilarsky, Irina Klaman, Stefan Roepcke, 2009, Journal of Molecular Medicine.

Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition

C. Ries, I. Klaman, T. Petrova, 2021, Science Translational Medicine.

Human Latrophilin-2 is Expressed in the Cytotrophoblast and Syncytiotrophoblast of Placenta and in Endothelial Cells

S. Taudien, I. Klaman, A. Sommer, 2005 .

Mutation Status of KRAS, BRAF, PIK3CA and Expression Level of AREG and EREG Identify Responders to Cetuximab in a Large Panel of Patient Derived Colorectal Carcinoma Xenografts of All Four UICC Stages

A. Rosenthal, I. Klaman, I. Fichtner, 2013 .

Tumor- and stromal cell-specific expression of topoisomerase IIα and HER-2/neu in primary and recurrent ovarian cancer: Results of a prospective study.

E. Dahl, A. Rosenthal, I. Klaman, 2009, Molecular medicine reports.

Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy.

E. Dahl, I. Klaman, W. Lichtenegger, 2006, Neoplasia.

The human LAPTM4b transcript is upregulated in various types of solid tumours and seems to play a dual functional role during tumour progression.

I. Petersen, E. Staub, D. Mennerich, 2005, Cancer letters.

Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours.

E. Dahl, A. Rosenthal, D. Mennerich, 2004, European journal of cancer.

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.

J. Blay, F. Feuerhake, A. Sica, 2014, Cancer cell.

T cell–induced CSF1 promotes melanoma resistance to PD1 blockade

G. Coukos, Esther Danenberg, N. Wald, 2018, Science Translational Medicine.

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients

J. Machiels, K. Korski, G. Meneses‐Lorente, 2020, Journal for ImmunoTherapy of Cancer.

Phase I Study of Emactuzumab Single Agent or in Combination with Paclitaxel in Patients with Advanced/Metastatic Solid Tumors Reveals Depletion of Immunosuppressive M2-like Macrophages.

J. Blay, M. Toulmonde, A. Italiano, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular Profiling of Laser-Microdissected Matched Tumor and Normal Breast Tissue Identifies Karyopherin α2 as a Potential Novel Prognostic Marker in Breast Cancer

Christian Pilarsky, Irina Klaman, Bernd Hinzmann, 2006, Clinical Cancer Research.

Abstract LB-085: RG70099: A novel, highly potent dual IDO1/TDO inhibitor to reverse metabolic suppression of immune cells in the tumor micro-environment

W. Muster, C. Fischer, I. Klaman, 2016 .

Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors.

Irina Klaman, Arndt Hartmann, Peter J Wild, 2004, International journal of oncology.

Expression and localization of e-cadherin in epithelial ovarian cancer.

E. Dahl, I. Klaman, W. Lichtenegger, 2010, Anticancer research.

Differential expression of genes encoding tight junction proteins in colorectal cancer: frequent dysregulation of claudin-1, -8 and -12

C. Pilarsky, A. Rosenthal, E. Staub, 2007, International Journal of Colorectal Disease.

Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis

M. Beckmann, P. Fasching, E. Dahl, 2012, BMC Cancer.

Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour.

J. Blay, M. Toulmonde, A. Italiano, 2020, European journal of cancer.

Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.

C. Denkert, E. Dahl, I. Klaman, 2007, Gynecologic oncology.

Systematic identification and molecular characterization of genes differentially expressed in breast and ovarian cancer

S. Gelling, J. Nährig, H. Höfler, 2005, The Journal of pathology.

ITIH5, a novel member of the inter-alpha-trypsin inhibitor heavy chain family is downregulated in breast cancer.

Irina Klaman, Bernd Hinzmann, Glen Kristiansen, 2004, Cancer letters.

Seamless Virtual Whole Slide Image Synthesis and Validation Using Perceptual Embedding Consistency

Nassir Navab, Shadi Albarqouni, Amal Lahiani, 2020, IEEE Journal of Biomedical and Health Informatics.

Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial

I. Klaman, J. Bendell, K. Lechner, 2023, Frontiers in Oncology.

Virtualization of tissue staining in digital pathology using an unsupervised deep learning approach

Nassir Navab, Shadi Albarqouni, Amal Lahiani, 2018, ECDP.

Generalising multistain immunohistochemistry tissue segmentation using end-to-end colour deconvolution deep neural networks

Nassir Navab, Amal Lahiani, Jacob Gildenblat, 2019, IET Image Process..

Generalizing multistain immunohistochemistry tissue segmentation using one-shot color deconvolution deep neural networks pdf

Nassir Navab, Amal Lahiani, Jacob Gildenblat, 2018, ArXiv.

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.

J. Blay, F. Feuerhake, A. Sica, 2014, Cancer cell.